Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has terminated the umbrella pact and transaction agreements with Daiichi Sankyo and its overseas subsidiaries due to divestment of Ranbaxy by the Japanese firm. Daiichi Sankyo, Daiichi Sankyo (Thailand), Sun Pharmaceutical Industries, Ranbaxy (Netherlands) BV and Ranbaxy (Thailand) Company entered into a termination agreement on May 26, 2016 and agreed that the umbrella agreement as well as the executed transaction agreements will be terminated with effect as of the closing date.

There is no material impact of such termination on either standalone or consolidated operations/ financial operations of the company. Additionally, the said termination agreement does not apply to, or have an impact upon, other business relationship that the parties to the said termination agreement may have in force.

Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. Its global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities.